Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy

Nicolò, Massimo; Zoli, Daniela; Musolino, Maria; Traverso, Carlo Enrico

doi:10.1016/j.ajo.2011.08.015

Cited by 54 publications

(71 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No complications were noted in the decreased-dose verterporfin group following PDT treatment. 17,19,21,22,29,35,47 Variation in Fluence: It is interesting to note that all of the studies with a variation in fluence had a recurrence of CSCR post PDT treatment within a 1-year-follow-up period. Recurrence rate of CSCR varied from 3 to 24%.…”

Section: Variation In Treatment Parametersmentioning

confidence: 99%

“…The remaining seventeen studies assessed the effect of different parameter variations in the standard TAP protocol in treating CSCR: reduced fluence (eight studies), reduced dose verteporfin (eight studies), variation in exposure time (one study). Two studies 17,22 were noted to have more than one variation in standard TAP protocol both of which used half-dose verteporfin and decreased irradiation time.…”

Section: Strobe-qualified Studiesmentioning

confidence: 99%

“…A similar pattern was noticed in Silva et al at 48 months with a reduction in CMT from 316 ± 114 to 169.7 ± 41.1 mm. 15,[17][18][19][20][21][22][23][24][25][26][27][29][30][31][33][34][35][36][37]46,47 Choroidal thickness on OCT Three studies assessed the choroidal thickness before and after PDT treatment (See Table 5 42 demonstrated that choroidal thickness in the area treated with PDT initially increased after treatment, then decreased. Pyrds and Larsen showed that choroidal thickness in the area where PDT was applied decreased from 407 mm (mean; 95% CI 356-458 mm) to 349 mm (mean; CI 95% 300-399 mm; Po0.0001), and subfoveal choroidal thickness was reduced from 421 mm (mean; CI 95% 352-489 mm) to 346 mm (mean; CI 95% 278-414 mm; P ¼ 0.0001).…”

Section: Variation In Treatment Parametersmentioning

confidence: 99%

“…Mean laser spot size ranged between 1300 and 6800mm. 15,[17][18][19][20][21][22][23][24][25][26][27][29][30][31][33][34][35][36][37]39,[41][42][43][44]46,47 Thirteen studies (n ¼ 13, 54.2%) used a mean spot size o4500 mm. The spot size was not mentioned in seven studies.…”

Section: Variation In Treatment Parametersmentioning

confidence: 99%

See 3 more Smart Citations

Photodynamic therapy for central serous chorioretinopathy

Erikitola

Crosby‐Nwaobi

Lotery

et al. 2014

Eye

View full text Add to dashboard Cite

Section: Variation In Treatment Parametersmentioning

confidence: 99%

Section: Strobe-qualified Studiesmentioning

confidence: 99%

Section: Variation In Treatment Parametersmentioning

confidence: 99%

Section: Variation In Treatment Parametersmentioning

confidence: 99%

See 2 more Smart Citations

Photodynamic therapy for central serous chorioretinopathy

Erikitola

Crosby‐Nwaobi

Lotery

et al. 2014

Eye

View full text Add to dashboard Cite

“…However, treatment success is limited by complications, including RPE atrophy and tears, choroidal neovascularization, and ischemia [18]. In an effort to minimize complications, PDT has been used at half the regular dose, fluence, or both [19][20][21][22][23]. This has been shown to reduce SRF doi: 10.7243/2055-2408-1-2 and improve visual acuity (VA) and retinal sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Half-dose and half-fluence photodynamic therapy for central serous chorioretinopathy

Rosenthal¹,

Flaxel²

2014

J Eye Ophthalmol

View full text Add to dashboard Cite

Background: Chronic central serous chorioretinopathy presents a treatment challenge. Photodynamic therapy has been used successfully but with side effects; thus, the authors explored half-dose and half-fluence photodynamic therapy as lower-risk alternatives. Methods: Retrospective medical record review of patients with chronic or recurrent central serous chorioretinopathy who received half-dose or half-fluence photodynamic therapy from May 2008 through March 2011 at a tertiary care referral center in Portland, Oregon, USA. The authors recorded demographics, visual acuity, and change in central retinal thickness as measured by optical coherence tomography. Results: Eight patients aged 46 to 80 years (11 eyes) were treated for central serous chorioretinopathy with half-dose or half-fluence photodynamic therapy, or with both of these treatment modalities on different occasions. Visual acuity before treatment ranged from 20/15 to 20/100; after treatment, visual acuity also ranged from 20/15 to 20/100. The authors noted no significant differences between half-dose and half-fluence photodynamic therapy and no serious treatment complications. Conclusions: Half-dose and half fluence photodynamic therapy are safe and effective treatment alternatives for chronic central serous chorioretinopathy.

show abstract

A 50% vs 30% Dose of Verteporfin (Photodynamic Therapy) for Acute Central Serous Chorioretinopathy

et al. 2015

View full text Add to dashboard Cite

IMPORTANCE A randomized clinical trial is needed to evaluate what is the best photodynamic therapy (PDT) protocol to use for acute central serous chorioretinopathy.OBJECTIVE To compare the efficacy and safety of a 50% dose of verteporfin (a method of PDT) with the efficacy and safety of a 30% dose for acute central serous chorioretinopathy. DESIGN, SETTING, AND PARTICIPANTSA multicenter, noninferiority, double-masked, randomized, controlled, clinical trial in which 131 patients (131 eyes) with acute central serous chorioretinopathy for less than 6 months were recruited with a follow-up of 12 months from university-based ophthalmology practices.INTERVENTIONS Patients were randomly assigned to either a 50% dose of verteporfin (the 50%-dose PDT group) or a 30% dose (the 30%-dose PDT group). MAIN OUTCOMES AND MEASURESThe 2 primary outcome measures were the proportion of eyes with complete absorption of subretinal fluid and the proportion of eyes with complete disappearance of fluorescein leakage at 6 and 12 months. The secondary outcome measures included the subretinal fluid recurrent rate, the fluorescein leakage recurrent rate at 12 months, the mean best-corrected visual acuity, the retinal thickness of the foveal center, and the maximum retinal thickness at each scheduled visit. RESULTSThe noninferiority of the 30%-dose PDT compared with the 50%-dose PDT for the primary outcomes was not demonstrated. The optical coherence tomography-based improvement rate in the 30%-dose PDT group was less than that in the 50%-dose PDT group both at 6 months (73.8% vs 92.9%; α = 0.0125, P = .006) and at 12 months (75.4% vs 94.6%; α = 0.0125, P = .004). The fluorescein angiography-based improvement rate in the 30%-dose PDT group was less than that in the 50%-dose PDT group both at 6 months (68.9% vs 91.1%; α = 0.0125, P = .003) and at 12 months (68.9% vs 92.9%; α = 0.0125, P = .001). The subretinal fluid recurrence rate in the 30%-dose PDT group was greater than that in the 50%-dose PDT group (24.0% vs 5.7% at 12 months; P = .010, determined by use of the log-rank test). The fluorescein leakage recurrent rate in the 30%-dose PDT group was significantly higher than that in the 50%-dose PDT group (16.7% vs 3.8% at 12 months; P = .03, determined by use of the log-rank test). No ocular adverse event was encountered in the study. CONCLUSIONS AND RELEVANCEA 50% dose of verteporfin may be more effective at resolving subretinal fluid and fluorescein leakage, and with better visual outcomes, than a 30% dose for acute central serous chorioretinopathy. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01574430

show abstract

Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy

Cited by 54 publications

References 12 publications

Photodynamic therapy for central serous chorioretinopathy

Photodynamic therapy for central serous chorioretinopathy

Half-dose and half-fluence photodynamic therapy for central serous chorioretinopathy

A 50% vs 30% Dose of Verteporfin (Photodynamic Therapy) for Acute Central Serous Chorioretinopathy

Contact Info

Product

Resources

About